Despite recording a one-time expense in Q2, the company remained profitable in the first half. Revenue was 1,499 million yen (YoY +500 million yen), operating profit was 0 million yen, and interim net profit was 4 million yen. The regenerative medicine products business achieved revenue growth across segments, and increased orders for JAC strengthened core earnings capacity. Full-year outlook remains unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7774","jir_company_name":"Japan Tissue Engineering Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/7774-20261030-02.pdf","jir_short_summary":"Despite recording a one-time expense in Q2, the company remained profitable in the first half. Revenue was 1,499 million yen (YoY +500 million yen), operating profit was 0 million yen, and interim net profit was 4 million yen. The regenerative medicine products business achieved revenue growth across segments, and increased orders for JAC strengthened core earnings capacity. Full-year outlook remains unchanged.","jir_summary":"### Overview of Results\nFor the first half of the fiscal year ending March 2027, the company recorded a one-time expense in Q2 but remained profitable overall. Revenue was 1,499 million yen, up 500 million yen year-over-year; operating profit (loss) was 0 million yen; and interim net profit (loss) was 4 million yen. The regenerative medicine products business drove revenue increases across segments. Orders for JAC expanded to 210 cases in the first half, totaling 326 cases cumulatively. Contracts for OA reached 158 facilities, while commissioned work from Teijin declined following completion of a know-how provision cycle. Overall, however, the company strengthened its underlying earnings power.\n\n### Outlook and Growth Initiatives\nWhile maintaining profitability in the first half, the company will promote order expansion and local deployment across the regenerative medicine products business. Jasmine will accelerate awareness and diffusion of treatments for vitiligo in Japan through a partnership with Maruho Co., Ltd. JAC will collaborate with OSB to promote combined therapies for cartilage repair and osteotomy. The company will expand its lab site business, including establishing a European subsidiary in Germany, and advance local expansion into the European market.","jir_financial_highlights":"Revenue: 1,499 (YoY +500 million yen)\nOperating Profit (Loss): 0 (YoY +376 million yen)\nInterim Net Profit (Loss): 4 (YoY +375 million yen)","jir_category":"","jir_hashtags":"#JapanTissueEngineering_tag_omitted #RegenerativeMedicine #FinancialPresentation","jir_key_figures":"Revenue: 1,499 million yen (YoY +500 million yen)\nOperating Profit (Loss): 0 million yen (YoY +376 million yen)\nInterim Net Profit (Loss): 4 million yen (YoY +375 million yen)","jir_meta_title":"Japan Tissue Engineering Co., Ltd. Second Quarter Financials for FY Mar 2027 | Revenue 1,499 million yen (+500)","jir_meta_description":"Financial presentation for Japan Tissue Engineering Co., Ltd. for the second quarter of FY ending March 2027. First-half results: revenue 1,499 million yen, operating profit 0 million yen, interim net profit 4 million yen. Summary of growth in regenerative medicine and future strategy.","jir_og_title":"Japan Tissue Engineering Co., Ltd. Announces Second Quarter Results","jir_og_description":"First-half revenue was 1,499 million yen with profitability maintained. Explains order growth in regenerative medicine and plans for global expansion.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"26\/3\u671f\\\",\\\"27\/3\u671f\u4e0a\u671f\\\"],\\\"datasets\\\":[{\\\"data\\\":[998,1499],\\\"label\\\":\\\"Revenue\\\"}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit (Loss) Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"26\/3\u671f\\\",\\\"27\/3\u671f\u4e0a\u671f\\\"],\\\"datasets\\\":[{\\\"data\\\":[-376,0],\\\"label\\\":\\\"Operating Profit (Loss)\\\"}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Regenerative Medicine Products\\\",\\\"Regenerative Medicine Contracting\\\",\\\"Lab Site\\\"],\\\"datasets\\\":[{\\\"data\\\":[1440,215,139],\\\"label\\\":\\\"Revenue\\\"}]}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating Profit\\\",\\\"Ordinary Income\\\"],\\\"datasets\\\":[{\\\"data\\\":[15,0,7],\\\"label\\\":\\\"Stage Margins\\\"}]}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Forecasts and Results\", \"jir_chart_json_data\": \"{\\\"headers\\\":[\\\"Metric\\\",\\\"FY2026 Actual\\\",\\\"FY2027 First Half Actual\\\"],\\\"rows\\\":[[\\\"Revenue\\\",\\\"999\\\",\\\"1499\\\"],[\\\"Operating Profit\\\",\\\"-376\\\",\\\"0\\\"],[\\\"Ordinary Income\\\",\\\"-369\\\",\\\"7\\\"]]}\"}]","ir_related_company":57771,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-137059","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n